ABSTRACT
Background COVID-19 is characterized by strikingly large, mostly unexplained, interindividual variation in symptom severity. While some individuals remain nearly asymptomatic, others suffer from severe respiratory failure. It has been hypothesized that previous vaccinations for other pathogens, in particular tetanus, may provide protection against severe COVID-19.
Methods We made use of data on COVID-19 testing from 103,049 participants of the UK Biobank (mean age 71.5 years, 54.2% female), coupled to immunization records of the last ten years. Using logistic regression, covarying for age, sex, respiratory disease diagnosis, and socioeconomic status, we tested whether individuals vaccinated for tetanus, diphtheria or pertussis, differed from individuals that had only received other vaccinations on 1) undergoing a COVID-19 test, 2) the outcome of this test, and 3) whether they developed severe COVID-19.
Results We found that individuals with registered diphtheria or tetanus vaccinations were less likely to develop severe COVID-19 than people who had only received other vaccinations (diphtheria OR=0.46, p=3.6×10−4; tetanus OR=0.50, p=5.8×10−4).
Discussion These results indicate that a history of diphtheria or tetanus vaccinations is associated with less severe manifestations of COVID-19. These vaccinations may protect against severe COVID-19 symptoms by stimulating the immune system. We note the correlational nature of these results, yet the possibility that these vaccinations may influence the severity of COVID-19 warrants follow-up investigations.
Competing Interest Statement
Dr. Andreassen has received speakers honorarium from Lundbeck, and is a consultant to HealthLytix. Mr. Pinzon-Espinosa has received CME-speaker honoraria from Lundbeck, Angelini, Neuraxpharma, and Janssen, all unrelated to the current work.
Funding Statement
The authors were funded by the Research Council of Norway (276082, 213837, 223273, 204966/F20, 229129, 249795/F20, 225989, 248778, 249795, 298646, 300767), the South-Eastern Norway Regional Health Authority (2013-123, 2014-097, 2015-073, 2016-064, 2017-004, 2019-101), Stiftelsen Kristian Gerhard Jebsen (SKGJ-Med-008), The European Research Council (ERC) under the European Union Horizon 2020 research and innovation programme (ERC Starting Grant, Grant agreement No. 802998), ERA-Net Cofund through the ERA PerMed project IMPLEMENT, and National Institutes of Health (R01MH100351, R01GM104400).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK National Health Service National Research Ethics Service (ref 11/NW/0382
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data incorporated in this work were gathered from public resources. Correspondence and requests for materials should be addressed to j.monereosanchez{at}maastrichtuniversity.nl and d.v.d.meer{at}medisin.uio.no.
